Immunocytochemical methodologies involving specific antibodies have demonstrated usefulness in detecting bone marrow micrometastases that are not detectable by conventional methods (Dearnaley et al., 1981) , and preliminary reports support the relevance of these metastatic cells in predicting tumour progression (Stahel et al., 1985) . In a recent conference on cancer micrometastases, a statistically significant association between the disease-free survival of patients with breast or colon carcinoma and the presence of cytokeratinpositive cells in the bone marrow was reported (Riethmuller & Johnson, 1992) . Multivariate analysis of those cases also indicated that bone marrow positivity is an independent predictor of tumour progression, and no correlation between tumour cells in the bone marrow and conventional prognostic factors was found (Riethmuller & Johnson, 1992) .
Early metastatic dissemination from the primary tumour to bone marrow, not correlated to other variables indicative of metastatic spread, might reflect differences in the biological characteristics of these tumours, such as an abnormal expression of an oncogene or other molecule related to invasiveness.
In a previous study, we investigated the presence of epithelial cells in bone marrow biopsies from breast carcinoma patients using a single monoclonal antibody (MAb) and immunofluorescence assay (Porro et al., 1988) . In an effort to increase the sensitivity of the analysis and to standardise the methodology to the most used one, we used a pool of five MAbs (Tagliabue et al., 1986) (Tagliabue et al., 1986) , and the CK-2 MAb (BoehringerMannheim, Tutzing, Germany), which recognises the cytokeratin component 18 present in simple epithelia, were used for analysis of bone marrow cytospun cells.
For primary tumour characterisation, a separate set of eight MAbs was used. MBrl and MBr8 are directed against breast differentiation antigens (Mariani-Costantini et al., 1984; Facheris et al., 1992) . MGR1 and MGR2 are directed, respectively, against the c-erbB-1 and the c-erbB-2 oncogene products Tagliabue et al., 1991) . MluC5 is directed against the 67 kDa laminin receptor (Martignone et al., 1992) . For integrin expression, the MAR4 and MAR6 MAbs directed respectively against the PI and a6 subunits Bottini et al., 1993) Milan, Italy. concentration of 5 tLg ml '. Tumours were considered positive when more than 10% of cells were reactive with the tested MAb.
Results
The clinical characteristics of the 197 consecutive patients with primary breast carcinoma examined in this study (Table  I) Fifty patients were then chosen based on their bone marrow positivity or negativity with the MAb pool and tested with the anti-cytokeratin CK-2 MAb. Of the 25 pool-positive samples, 21 contained cytokeratin-positive cells, whereas only three of the 25 pool-negative cases were CK-2 positive. The correlation between the reactivity of the two reagents is highly statistically significant (P<0.001).
Statistical analysis to determine any association between the presence of pool-immunoreactive cells in the bone marrow and other clinical and biological parameters (Table II) indicated that bone marrow positivity was correlated with tumour grade in that grade I tumours were almost all bone marrow negative. For the other parameters, no significant differences were found between the bone marrow-negative and bone marrow-positive groups, although patients in the latter group were more frequently lymph node positive, with oestrogen and progesterone receptor-positive tumours of small diameter and with a low proliferation rate.
The primary tumours were also analysed for the expression of different markers related to differentiation and to oncogene and adhesion receptor expression. The expression of the 6-and P4-integrin subunits was always superimposable, whereas PI was found in almost all the tumours in a homogeneous distribution. The only statistically significant difference (P<0.01) between the bone marrow-positive and bone marrow-negative group was in expression of the 67 kDa laminin receptor in the primary tumours, enhanced expression being more frequent in the marrow-positive cases (Table  III) . Less differentiated tumours (as indicated by MAb MBrl and MBr8 non-reactivity) that overexpressed the c-erbB-1 oncogene product tended to be associated with the bone marrow-positive group, whereas a borderline negative association was found for c-erbB-2 overexpression, i.e. tumours of the bone marrow-positive group were less frequently positive for c-erbB-2 expression.
To investigate the prognostic significance of expression of the 67 kDa laminin receptor in this patient series, this parameter was analysed in association with some clinical and biological parameters (Table IV) . Indeed, the presence of this receptor in the primary tumour was strongly associated with lymph node metastasis (P<0.01), in addition to the association with bone marrow positivity (Table III) . No association with other parameters was found. (Porro et al., 1988; Salvadori et al., 1990) , using only one of these MAbs (MBrl) on cells isolated from bone marrow biopsies, only 17% of the patients were found to be positive, indicating that many positive cases were not diagnosed. With the new pool tested on bone marrow aspirates, the percentage of positive patients (31%) is very similar to that reported by others on similar samples (Mansi et al., 1987; Schlimok et al., 1987; Cote et al., 1988 Cote et al., , 1991 using different anti-epithelial reagents. The higher positivity we found on aspirates vs biopsies could be due not only to the use of a pool of MAbs instead of a single MAb, but also to the gradient separation procedure of the cells from aspirates, which might concentrate the tumour cells in the sample. Our finding that the MAb pool-positive cases also showed reactivity with the CK-2 anti-cytokeratin MAb, which was the reagent used in two of the three other studies (Schlimok et al., 1987; Ellis et al., 1989) , together with the similar percentage of positivity, strongly suggests that all of these studies actually detect the same cell type and that the prognostic significance described in two patient series (Dearnaley et al., 1991; Riethmuller & Johnson, 1992) can probably be extended to the other studies. The follow-up of our patient series now in progress should clarify this issue. Consistent with observations in the other studies, we found that the presence of positive cells in the bone marrow of our patients is independent of other clinical parameters indicative of the stage of disease, such as tumour size and lymph node metastasis (Riethmuller & Johnson, 1992) , but correlates with the tumour grade; indeed, well-differentiated tumours as also evaluated by marker expression had immunoreactive cells in the bone marrow less frequently. Further, the laminin receptor is more frequently expressed in the primary tumours of patients with bone marrow spread than in those patients with no epithelial cells detectable in the marrow. This receptor, also associated with lymphatic spread, appears to identify tumours with metastatic potential, independent of the site of origin; the prognostic relevance of laminin receptor expression in breast carcinomas has recently been defined on a series of 1,150 patients (Martignone et al., 1993) . It remains to establish whether finding epithelial cells in the bone marrow adds to the prognostic value of laminin receptor expression. The mechanism of action of the 67 kDa laminin receptor is still unknown, but is probably not limited to laminin binding. Indeed, the expression of other laminin receptors such as a6/P1 (VLA-6) and a6/P4 seems to be unrelated to metastatic spread. On the contrary, a6-subunit expression is reported to decrease during tumour progression (Zutter et al., 1993) and the x6-subunit may behave as a tumour-suppressor gene (Sager et al., 1993) .
The borderline negative correlation between overexpression of the c-erbB-2 oncogene and bone marrow reactivity was unexpected. In fact, the oncogene-positive tumours, which have been associated with poor prognosis, were more frequently negative at the bone marrow level. Consistent with this observation is the recent finding of a peculiar metastatic distribution of c-erbB-2-positive breast carcinomas, which induce bone metastasis less frequently than the negative ones (Kallioniemi et al., 1991) .
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